<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060099</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000299462</org_study_id>
    <secondary_id>BWH-000-P-CONS01</secondary_id>
    <secondary_id>NCI-3074</secondary_id>
    <nct_id>NCT00060099</nct_id>
  </id_info>
  <brief_title>SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia</brief_title>
  <official_title>Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber/Brigham and Women's Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of or treat early cancer. SGN-00101 may be effective in preventing the&#xD;
      development of cervical cancer in patients with cervical intraepithelial neoplasia.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well SGN-00101 works in preventing&#xD;
      cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of SGN-00101 vs placebo in patients with grade II or III cervical&#xD;
           intraepithelial neoplasia.&#xD;
&#xD;
        -  Correlate clinical response, as defined by histologic demonstration of lesion&#xD;
           regression, with potential surrogate markers of vaccine efficacy (e.g., spectroscopic&#xD;
           changes in the epithelium, development of human papilloma virus (HPV)-specific mucosal&#xD;
           and systemic T-cell responses, and levels of HPV-specific antibody in cervical&#xD;
           secretions), in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind study. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive SGN-00101 subcutaneously (SC) once a month for 3 consecutive&#xD;
           months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive placebo SC as in arm I. Patients are followed monthly for 3&#xD;
           months after the last injection and then undergo large loop excision of the&#xD;
           transformation zone under colposcopy at the fourth month. Patients with disease&#xD;
           progression undergo immediate large loop excision.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 80 patients (40 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HspE7</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed grade II or III cervical intraepithelial neoplasia&#xD;
&#xD;
               -  Confirmed by colposcopy-directed punch biopsy&#xD;
&#xD;
          -  Accessible, definable, and entirely visible cervical lesions persisting after biopsy&#xD;
&#xD;
               -  Satisfactory colposcopic exam within 3-6 weeks after diagnostic biopsy&#xD;
&#xD;
          -  Positive for human papilloma virus 16&#xD;
&#xD;
          -  CD4+ counts normal&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No coagulation disorder that requires medical intervention&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B core antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiovascular disorder that requires medical intervention&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No respiratory disorder that requires medical intervention&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not immunologically compromised&#xD;
&#xD;
          -  No prior severe allergic reactions (anaphylactic response) to drugs or any other&#xD;
             allergen&#xD;
&#xD;
          -  No immunological disorders including any of the following:&#xD;
&#xD;
               -  Lupus&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
          -  No active systemic infections that require medical intervention&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to undergo a loop electrosurgical excision procedure&#xD;
&#xD;
          -  No medical or psychiatric illness that would preclude study treatment, ability to give&#xD;
             informed consent, or study compliance&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent gene therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 30 days since prior systemic steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin A. Keefe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber/Brigham and Women's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>cervical intraepithelial neoplasia grade 2</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <keyword>human papilloma virus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

